Lipid Profile among Type 2 Diabetes Patients with Polymorphisms rs628031 A>G and rs2289669 G>A in Metformin Transporter Genes
Keywords:diabetes, lipid profile, metformin transporter gene, single nucleotide polymorphism
Background: Metformin affects not only glucose, but also lipid metabolism. The uptake of metformin in the liver is mainly mediated by transporters OCT1and OCT2 (encoded by SLC22A1 gene), whereas MATE1 (encoded by SLC47A1 gene) is responsible for its elimination into the urine and bile. We investigated the interaction between SLC22A1 rs628031 and SLC47A1 rs2289669 variants with the lipid profile of type 2 diabetes (T2DM) patients consuming metformin.
Methods: Sociodemographic data, metformin consumption and laboratory data of 23 T2DM participants were obtained from medical records at Bhayangkara Hospital, Palembang. DNA from whole blood was extracted using the Chelex method. Polymerase chain reaction was carried out, followed by restriction fragment length polymorphism detection using restriction enzymes. Polymorphism was assessed by electrophoresis and visualization on agarose gel.
Results: There was no significant association between SLC22A1 rs628031 and SLC47A1 rs2289669 with the lipid profile of T2DM patients (p>0.05). However, there was an increased trend of total cholesterol and LDL levels in patients with rs628031 variants compared to wildtype.
Conclusion: Further study with large cohorts is needed to confirm the association between these two single nucleotide polymorphisms and lipid profile, as we showed a particular trend of lipid profile for those with rs628031 variants.
American Diabetes Association, “Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020,” Diabetes Care, vol. 43, no. Supplement_1, pp. S98–S110, 2020.
M. O. Goodarzi and M. Bryer‐Ash, “Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents,” Diabetes, Obesity and Metabolism, vol. 7, no. 6, pp. 654–665, 2005.
L. Gong, S. Goswami, K. M. Giacomini, R. B. Altman, and T. E. Klein, “Metformin pathways: pharmacokinetics and pharmacodynamics,” Pharmacogenetics and Genomics, vol. 22, no. 11, p. 820, 2012.
M. M. Christensen et al., “The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c,” Pharmacogenetics and Genomics, vol. 21, no. 12, pp. 837–850, 2011.
J. König, O. Zolk, K. Singer, C. Hoffmann, and M. Fromm, “Double‐transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations,” British Journal of Pharmacology, vol. 163, no. 3, pp. 546–555, 2011.
C. Arimany-Nardi, H. Koepsell, and M. Pastor-Anglada, “Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug–drug interactions,” The Pharmacogenomics Journal, vol. 15, no. 6, pp. 473–487, 2015.
R. Kerb et al., “Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences,” Pharmacogenetics and Genomics, vol. 12, no. 8, pp. 591–595, 2002.
M. Becker, L. Visser, R. Van Schaik, A. Hofman, A. Uitterlinden, and B. Stricker, “Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus,” The Pharmacogenomics Journal, vol. 9, no. 4, pp. 242–247, 2009.
A. T. Nies et al., “Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver,” Hepatology, vol. 50, no. 4, pp. 1227–1240, 2009.
E. Shikata et al., “Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin,” Journal of Human Genetics, vol. 52, no. 2, pp. 117–122, 2007.
Y. Shu et al., “Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1422–1431, 2007.
M. Tsuda, T. Terada, T. Mizuno, T. Katsura, J. Shimakura, and K. Inui, “Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin,” Molecular Pharmacology, vol. 75, no. 6, pp. 1280–1286, 2009.
M. L. Becker, L. E. Visser, R. H. van Schaik, A. Hofman, A. G. Uitterlinden, and B. H. C. Stricker, “Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study,” Diabetes, vol. 58, no. 3, pp. 745–749, 2009.
M. L. Becker, L. E. Visser, R. H. van Schaik, A. Hofman, A. G. Uitterlinden, and B. H. C. Stricker, “Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response,” Pharmacogenetics and Genomics, vol. 20, no. 1, pp. 38–44, 2010.
T. Rankinen, M. A. Sarzynski, S. Ghosh, and C. Bouchard, “Are there genetic paths common to obesity, cardiovascular disease outcomes, and cardiovascular risk factors?,” Circulation Research, vol. 116, no. 5, pp. 909–922, 2015.
X. Liang et al., “Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content,” PLoS biology, vol. 16, no. 4, p. e2002907, 2018.
American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 37, no. Supplement_1, pp. S81–S90, 2014.
C. Glueck et al., “Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30,” Metabolism-Clinical and Experimental, vol. 50, no. 7, pp. 856–861, 2001.
J. J. Geerling et al., “Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice,” Diabetes, vol. 63, no. 3, pp. 880–891, 2014.
M. Zang et al., “AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells,” Journal of Biological Chemistry, vol. 279, no. 46, pp. 47898–47905, 2004.
L. Chen et al., “Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 42–50, 2010.
V. D. Ningrum, Z. Ikawati, A. H. Sadewa, and M. R. Ikhsan, “Allele frequencies of two main metformin transporter genes: SLC22A1 rs628031 A> G and SLC47A1 rs2289669 G> A among the Javanese population in Indonesia,” Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), vol. 15, no. 2, pp. 121–128, 2017.
T. Dujic et al., “Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes,” Diabetic Medicine, vol. 33, no. 4, pp. 511–514, 2016.
F. Shokri et al., “Impact of ATM and SLC22A1 polymorphisms on therapeutic response to metformin in Iranian diabetic patients,” International Journal of Molecular and Cellular medicine, vol. 5, no. 1, p. 1, 2016.
L. Tarasova et al., “Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients,” Pharmacogenetics and Genomics, vol. 22, no. 9, pp. 659–666, 2012.
Y. Zhou et al., “Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai,” International Journal of Clinical and Experimental pathology, vol. 8, no. 8, p. 9533, 2015.
E. P. M. Mato, M. Guewo-Fokeng, M. F. Essop, and P. M. O. Owira, “Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review,” Medicine, vol. 97, no. 27, 2018.
A. Yonezawa and K. Inui, “Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics,” British Journal of Pharmacology, vol. 164, no. 7, pp. 1817–1825, 2011.
I. Tkáč et al., “Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 15, no. 2, pp. 189–191, 2013.
How to Cite
Copyright (c) 2023 Indonesian Archives of Biomedical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.